Lung-selective 25-hydroxycholesterol nanotherapeutics as a suppressor of COVID-19-associated cytokine storm
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, H. | - |
dc.contributor.author | Lee, H.S. | - |
dc.contributor.author | Ahn, J.H. | - |
dc.contributor.author | Hong, K.S. | - |
dc.contributor.author | Jang, J.G. | - |
dc.contributor.author | An, J. | - |
dc.contributor.author | Mun, Y.-H. | - |
dc.contributor.author | Yoo, S.-Y. | - |
dc.contributor.author | Choi, Y.J. | - |
dc.contributor.author | Yun, M.-Y. | - |
dc.contributor.author | Song, G.Y. | - |
dc.contributor.author | Joo, J. | - |
dc.contributor.author | Na, D.H. | - |
dc.contributor.author | Kim, H.N. | - |
dc.contributor.author | Park, H.H. | - |
dc.contributor.author | Lee, J.-Y. | - |
dc.contributor.author | Lee, W. | - |
dc.date.accessioned | 2022-01-20T06:41:02Z | - |
dc.date.available | 2022-01-20T06:41:02Z | - |
dc.date.issued | 2021-06 | - |
dc.identifier.issn | 1748-0132 | - |
dc.identifier.issn | 1878-044X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/53999 | - |
dc.description.abstract | In response to the coronavirus disease-19 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), global efforts are focused on the development of new therapeutic interventions. For the treatment of COVID-19, selective lung-localizing strategies hold tremendous potential, as SARS-CoV-2 invades the lung via ACE2 receptors and causes severe pneumonia. Similarly, recent reports have shown the association of COVID-19 with decreased 25-hydroxycholesterol (25-HC) and increased cytokine levels. This mechanism, which involves the activation of inflammatory NF-κB- and SREBP2-mediated inflammasome signaling pathways, is believed to play a crucial role in COVID-19 pathogenesis, inducing acute respiratory distress syndrome (ARDS) and sepsis. To resolve those clinical conditions observed in severe SARS-CoV-2 patients, we report 25-HC and didodecyldimethylammonium bromide (DDAB) nanovesicles (25-HC@DDAB) as a COVID-19 drug candidate for the restoration of intracellular cholesterol level and suppression of cytokine storm. Our data demonstrate that 25-HC@DDAB can selectively accumulate the lung tissues and effectively downregulate NF-κB and SREBP2 signaling pathways in COVID-19 patient-derived PBMCs, reducing inflammatory cytokine levels. Altogether, our findings suggest that 25-HC@DDAB is a promising candidate for the treatment of symptoms associated with severe COVID-19 patients, such as decreased cholesterol level and cytokine storm. © 2021 The Author(s) | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier B.V. | - |
dc.title | Lung-selective 25-hydroxycholesterol nanotherapeutics as a suppressor of COVID-19-associated cytokine storm | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.nantod.2021.101149 | - |
dc.identifier.bibliographicCitation | Nano Today, v.38 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000670246400002 | - |
dc.identifier.scopusid | 2-s2.0-85104142126 | - |
dc.citation.title | Nano Today | - |
dc.citation.volume | 38 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | 25-hydroxycholesterol | - |
dc.subject.keywordAuthor | Didodecyldimethylammonium bromide | - |
dc.subject.keywordAuthor | Lung-selective nanohybrids | - |
dc.subject.keywordAuthor | Sepsis | - |
dc.subject.keywordAuthor | Severe COVID-19 | - |
dc.subject.keywordPlus | Biological organs | - |
dc.subject.keywordPlus | Cholesterol | - |
dc.subject.keywordPlus | Patient treatment | - |
dc.subject.keywordPlus | Storms | - |
dc.subject.keywordPlus | Acute respiratory distress syndrome | - |
dc.subject.keywordPlus | Cholesterol levels | - |
dc.subject.keywordPlus | Clinical conditions | - |
dc.subject.keywordPlus | Didodecyldimethylammonium bromide | - |
dc.subject.keywordPlus | Intracellular cholesterol | - |
dc.subject.keywordPlus | Severe acute respiratory syndrome coronavirus | - |
dc.subject.keywordPlus | Signaling pathways | - |
dc.subject.keywordPlus | Therapeutic intervention | - |
dc.subject.keywordPlus | Diseases | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Nanoscience & Nanotechnology | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Multidisciplinary | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.